Related Experiment Videos
Effect of ipratropium bromide on repeated methacholine challenges
Annals of Allergy
|December 1, 1985
Summary
Ipratropium bromide (IB) effectively protected most asthma patients from methacholine-induced bronchoconstriction one hour after administration. Its protective effect diminished by four hours but still benefited a majority, demonstrating significant bronchodilating action.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- Asthma management often involves inhaled bronchodilators.
- Assessing the duration of action for inhaled medications is crucial for patient care.
Purpose of the Study:
- To evaluate the protective efficacy of ipratropium bromide (IB) against methacholine inhalation challenge (MIC) at one and four hours post-administration.
- To determine the bronchodilating effect of IB compared to placebo.
Main Methods:
- Twenty asthma patients underwent methacholine inhalation challenge (MIC) to determine the provocative dose causing a 20% drop in FEV1 (PD20-FEV1).
- Patients received ipratropium bromide (IB) via inhaler (0.04 mg total dose) or placebo.
- Bronchial reactivity was reassessed at one and four hours after IB administration.
Main Results:
- Ipratropium bromide (IB) significantly protected 19 out of 20 patients from MIC at one hour post-administration, compared to zero patients protected by placebo.
- A significant bronchodilating effect was observed one hour after IB administration.
- At four hours post-administration, IB still protected 13 out of 20 patients from methacholine challenge.
Conclusions:
- Ipratropium bromide (IB) provides significant protection against methacholine-induced bronchoconstriction one hour after inhalation.
- The bronchodilating effect of IB persists for at least four hours in a majority of asthma patients.
- IB is an effective treatment for managing acute bronchoconstriction in asthma.